$LGND Recent News A portfolio rotation for a

New Post Public Reply Private Reply Replies (0) Message Board

Dec 3, 2013 at 4:43 PM

$LGND Recent News

A portfolio rotation for a medium-term speculator
11:41 a.m. Oct. 29, 2013
- The Trading Deck

Leading growth titles stand tall
12:30 p.m. Oct. 17, 2013
- The Trading Deck

Forest Oil shares surge on Texas asset sale
4:48 p.m. Oct. 3, 2013
- Wallace Witkowski

Pfizer, Ligand menopause drug gets FDA approval
4:19 p.m. Oct. 3, 2013
- MarketWatch.com

Stock leaders stand strong, despite drift
12:13 p.m. Sept. 26, 2013
- The Trading Deck

A bull market not ready to be put to rest
11:14 a.m. Sept. 5, 2013
- The Trading Deck

Trade what you see, not what you believe
12:30 p.m. Aug. 29, 2013
- The Trading Deck

Ligand lifts '13 outlook; signs a license deal
6:44 a.m. March 14, 2013
- MarketWatch.com

Ligand, Glaxo win expanded approval for Promacta
10:13 a.m. Nov. 19, 2012
- MarketWatch.com

12 biotech stocks hit 52-week highs
2:43 p.m. July 27, 2012
- Val Brickates Kennedy

Seagate, US Airways among top picks of Sabrient's Brown

9:34 a.m. May 4, 2012
- blogs.marketwatch.com

Pfizer to seek OK for long-stalled menopause drug
1:17 p.m. Jan. 30, 2012
- MarketWatch.com

How corporate insiders reacted to Japan
11:01 p.m. March 22, 2011
- Mark Hulbert

Somaxon paces decliners in drug sector
11:12 a.m. Nov. 19, 2010
- Val Brickates Kennedy

Insider Trading Alert - NVR, AN, PPS, BRCM And LGND Traded By Insiders

10:15 a.m. Dec. 2, 2013
- TheStreet.com

Goldman reiterates bullish rating on Amgen, sees Kyprolis sales ahead of consensus

11:27 a.m. Nov. 29, 2013
- Seeking Alpha

Ligand Pharmaceuticals (LGND) Jumps: Stock Rises 5.5% - Tale of the Tape

8:44 a.m. Nov. 27, 2013
- Zacks.com

Ligand rebounds as Summer Street strikes upbeat tone on Kyprolis

9:50 a.m. Nov. 22, 2013
- Seeking Alpha

BofA note spooks Amgen, Ligand investors

3:20 p.m. Nov. 21, 2013
- Seeking Alpha

A Few Stocks Form Bases, But Have Flaws

5:30 p.m. Nov. 20, 2013
- Investors Business Daily

Ligand Pharmaceuticals On Pace For Annual Profit

4:25 p.m. Nov. 5, 2013
- Investors Business Daily

Ligand Pharmaceuticals Incorporated Management Discusses Q3 2013 Results - Earnings Call Transcript

3:20 p.m. Oct. 30, 2013
- Seeking Alpha

Short Interest Makes 14.4% Move For LGND

3:40 p.m. Oct. 25, 2013
- TheStreet.com

Ligand, NIC: Thinly Traded Stocks That Hold Promise

4:17 p.m. Oct. 24, 2013
- Investors Business Daily

Pfizer: The Menopause Opportunity

5:45 p.m. Oct. 18, 2013
- Seeking Alpha

Hedge Funds Are Buying 8 Rallying Healthcare Stocks Benefitting From Obamacare

5:05 p.m. Oct. 15, 2013
- TheStreet.com

Put A Royalty Legend In Your Portfolio With Ligand Pharmaceuticals

8:25 a.m. Oct. 15, 2013
- Seeking Alpha

Amgen: GSK's Promacta Stealing Nplate's Thunder

11:47 a.m. Oct. 11, 2013
- Seeking Alpha

Pfizer: Pregnant Horses And Menopausal Women Bring In A Small Fortune

5:13 p.m. Oct. 9, 2013
- Seeking Alpha

IND for Ligand's LGD-6972 Accepted - Analyst Blog

6:07 p.m. Oct. 8, 2013
- Zacks.com

Did Pfizer and Ligand Just Get a New Winning Drug Approved?

4:07 p.m. Oct. 7, 2013
- Wall St. Cheat Sheet

FDA Approves New Hot Flash Treatment for Menopause

4:33 a.m. Oct. 4, 2013
- InvestorPlace.com

Five FDA Approvals and Reviews at Risk Under a Government Shutdown
9:49 a.m. Sept. 30, 2013
- 247WallSt.com

First Week Of May 2014 Options Trading For Ligand Pharmaceuticals (LGND)

12:04 p.m. Sept. 27, 2013
- TheStreet.com

FDA Approvals, Scheduled Presentations, and Stock Price Movements - Research Report on Amgen, St. Jude Medical, Life Technologies, Ligand, and Infinity Pharmaceuticals
8:00 a.m. Nov. 29, 2013
- PR Newswire

Ligand Pharmaceuticals Set to Join the S&P SmallCap 600
5:37 p.m. Nov. 25, 2013
- PR Newswire

Financial Results, Agreements, Meetings, and Clinical Trials - Research Report on Cell Therapeutics, Akorn, Ligand, Intercept Pharmaceuticals and Ariad Pharmaceuticals
8:00 a.m. Nov. 20, 2013
- PR Newswire

Ligand Announces Highlights from Today's Analyst Day Event
4:05 p.m. Nov. 14, 2013
- BusinessWire

Ligand Initiates Phase 1 Trial with Glucagon Receptor Antagonist for Type 2 Diabetes
8:00 a.m. Nov. 12, 2013
- BusinessWire

Upcoming Conferences, Financial Results, Dividends, and Public Offerings - Research Report on Medicines Company, Isis, Ligand, Teleflex, and Tetraphase
8:00 a.m. Nov. 12, 2013
- PR Newswire

Reminder: Ligand to Host Analyst Day on November 14th in Chicago
8:00 a.m. Nov. 7, 2013
- BusinessWire

Healthcare Sector Announced Financial Results - Research Report on Ligand, Auxilium, STERIS, USANA, and Cardiovascular Systems
8:00 a.m. Nov. 4, 2013
- PR Newswire

New Appointments, Upcoming Earnings Releases, Regulatory Approvals, Status Updates and Informative Resources for New Treatment Options - Research Report on Mylan, Alkermes, Salix, Ligand and Hospira
8:31 a.m. Oct. 30, 2013
- PR Newswire

Ligand Reports Third Quarter Financial Results
7:30 a.m. Oct. 30, 2013
- BusinessWire

Ligand to Host Analyst Day on November 14th in Chicago
3:00 p.m. Oct. 14, 2013
- BusinessWire

Ligand to Report Third Quarter Results on October 30th
3:00 p.m. Oct. 9, 2013
- BusinessWire

Ligand Announces FDA Acceptance of Investigational New Drug Application for Glucagon Receptor Antagonist Program
7:00 a.m. Oct. 7, 2013
- BusinessWire

Ligand Partner Pfizer Receives FDA Approval for DUAVEE(TM) for the Treatment of Moderate-to-Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause and the Prevention of Postmenopausal Osteoporosis
4:00 p.m. Oct. 3, 2013
- BusinessWire

Regulatory Approval, New Appointments, Stock Price Movements, and Other Announcements - Research Report on Pfizer, Warner Chilcott, Rockwell Medical, InterMune, and Ligand
7:00 a.m. Oct. 2, 2013
- PR Newswire

Ligand Partner GSK Receives Marketing Authorization from the European Commission for Additional Revolade(TM) (Eltrombopag) Indication as the First Approved Treatment for Chronic Hepatitis C-Associated Thrombocytopenia
6:00 a.m. Sept. 24, 2013
- BusinessWire

Ligand Enters Global License Agreement with CURx Pharmaceuticals, Inc. for Captisol-Enabled(TM) Topiramate Injection
7:00 a.m. Aug. 14, 2013
- BusinessWire

RDInvesting Provides Investors with Free In-Depth Equity Reports on HALO, LGND, PCRX and SQI
7:51 a.m. Aug. 5, 2013
- ACCESSWIRE

Ligand Reports Second Quarter Financial Results
7:30 a.m. Aug. 1, 2013
- BusinessWire

New License Agreements and Financial Results Release - Research Report on Elan, Waters, InterMune, Spectranetics, and Ligand
7:00 a.m. July 29, 2013
- PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SHOPLINE's Pitch Day: 14 Brands in the Spotlight

SHOPLINE's Los Angeles Event Highlights Emerging Brands Flip the calendar back to October 1, and you'll find me soaking in the scene at the sprawling halls of SHOPLINE and Plug and Play’s latest event. This wasn’t your run-of-the-mill networking affair; it was a caffeine-fueled, adrenaline-pumping showcase of 14 up-and-coming consumer brands. Now, if there's one thing...

Vensure Launches Nationwide Background Casting Service

Vensure Dives into the World of Background Casting You ever consider just how chaotic a film or TV set can get? One minute things are all glitz and glam, and the next, it's pure mayhem as everything descends into a frenzied dance of coordination chaos. That's the circus of background casting for ya. Vensure's latest venture, Vensure Casting, throws its hat in the ring,...

Guidebook for Grounded Masculinity: A Fresh Insight

New Chapter in Masculinity: Navigating the Maze Leslie Grace Eggenberger's new workbook, Becoming a Man, wades right into the tangled mess of modern masculinity, sidestepping the usual lip service about toxic behaviors. Instead, it's offering an honest-to-goodness roadmap for grounded manhood, framed around five pivotal principles: Presence, Purpose, Proactivity,...

American Prosperity Rises Despite Economic Concerns

Reading Between the Lines of Prosperity You'd think the headlines scream gloom—job insecurity, a shaky economy, ridiculous basic cost hikes. Yet, against the odds like an underdog scrapping past the finish line, the Northwestern Mutual's Personal Prosperity Index crawled up to 71 out of 100, up by a humble three points since mid-year. Unlocking Prosperity in Chaotic...

Crocs™ Gains C2C Circularity Gold for Classic Clogs

Turning Plastic into Gold Well, folks, Crocs isn't just about comfort anymore. They're wrapping their iconic Classic Clog in a shiny new accolade: Cradle to Cradle Certified® Circularity Gold Version 5.0. Imagine that—an award for making something meant to last, designed to be repurposed. They're not just slapping new paint on the same old clogs either. This...

Tulsa Hosts Gradient's Global Tech and Investment Event

Tulsa's New Spotlight: Gradient's CHROMA Event Well, look at Tulsa, becoming the center of the tech and enterprise universe for a day. Gradient is throwing open the doors for its second annual CHROMA event on September 24, 2026. You might scratch your head and say, ‘Tulsa? Really?’ But hear me out—this isn’t just a local shindig. We're talking about a one-day...

Nucleus Reveals 2026 CPQ Value Chart for Manufacturers

CPQ Tech: Unpacking the 2026 Manufacturing Landscape In the cutthroat world of manufacturing, it's adapt or die. Right now, happens it's the fixers in Configure, Price, Quote (CPQ) technology, stepping in to save the day. Nucleus Research just dropped their 2026 Manufacturing CPQ Technology Value Matrix, shining a bright spotlight on who’s leading the pack and why it...

PG&E, Edison Push Liability Cap Amid Firestorm

The Thanksgiving Playbook Nobody Wanted Sacramento's corridors are buzzing with electric tension. And why? It's not some trivial turkey drama but a simmering scandal over two utility giants trying to sneak a liability cap into law faster than you can ask for a second slice of pumpkin pie. PG&E and Edison have a little secret—a covert strategy to limit shareholder...

Ian Marx Wins Pro Bono Honor at NJ Legal Awards

A Champion in Legal Advocacy How often do we hear about a lawyer choosing the unglamorous path of pro bono work over the high-stakes allure of corporate law? Slam-dunk, you don’t. At the New Jersey Legal Awards, Ian S. Marx from Greenberg Traurig broke the mold, snagging the 'Pro Bono Lawyer of the Year' award. This isn’t just some pat on the back; it's recognition of...

AllianceBernstein Unveils Income-Focused ETF Amid Volatile Times

Diving into AllianceBernstein's New Income ETF Well, today we’ve got something stirring in the financial waters over at AllianceBernstein. They’ve launched a new exchange-traded fund (ETF), aptly named the AB Equity Premium Income ETF [INK]. Now, if you’re wondering what’s cooking with this newcomer on the NASDAQ, let’s crack it open and see what’s under the...